Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Consolidated Net Income (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Consolidated Net Income for 10 consecutive years, with -$6.0 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income changed N/A to -$6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$26.3 million for FY2025, N/A changed from the prior year.
  • Consolidated Net Income hit -$6.0 million in Q4 2025 for Aptevo Therapeutics, up from -$7.6 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $946000.0 in Q1 2023 to a low of -$7.6 million in Q3 2025.
  • Historically, Consolidated Net Income has averaged -$1.7 million across 4 years, with a median of $157000.0 in 2022.
  • Biggest five-year swings in Consolidated Net Income: tumbled 96.79% in 2021 and later surged 431.46% in 2023.
  • Year by year, Consolidated Net Income stood at $325000.0 in 2021, then surged by 60.31% to $521000.0 in 2022, then plummeted by 43.76% to $293000.0 in 2023, then tumbled by 2146.42% to -$6.0 million in 2025.
  • Business Quant data shows Consolidated Net Income for APVO at -$6.0 million in Q4 2025, -$7.6 million in Q3 2025, and -$6.2 million in Q2 2025.